Forbion, a Naarden, The Netherlands- and Munich, Germany-based life science venture capital firm, held the final close of its new flagship fund, Forbion IV, at €360m.
Forbion IV attracted both new and existing blue-chip investors. New investors include UK based Pantheon, Dutch institutions ASR Insurances and the TNO Pension Fund, Nordic investors Formuesforvaltning and KLP, and some undisclosed North American institutional investors. Existing LPs European Investment Fund and development bank KfW also returned in the new fund.
The fund will focus on biopharma investments, built around new science, proven management teams or assets sourced from the pharmaceutical industry.
It will target substantial initial stakes, looking to take lead positions and work alongside entrepreneurial management teams. Forbion IV will build a portfolio of approximately fifteen companies, of which five will be new companies (co)founded by the firm and ten will be existing, growth companies.
The fund will primarily focus on opportunities in the EU including the UK, with the remainder of the fund targeting opportunities mainly in North America.
The €183m Forbion III already delivered 4 exits including the sale of Rigontec to MSD and the IPO of Replimune on NASDAQ in July 2018.
The firm is led by Sander Slootweg, Managing Partner and co-founder, and Robbert van de Griendt, General Partner and Head of Investor Relations and Impact, among others.